Sun Pharmaceutical Industries Ltd. Share Price

Sensex Outlook for 06-Oct-2026 Looks Range Bound

The Sensex ended its four-day losing streak on Monday, 5 October 2026, closing 472.77 points higher (0.66%) at 72,382.47. This positive momentum forms the technical foundation for the upcoming trading session on Tuesday, 6 October 2026. The Daily MACD Histogram is below zero and the Hourly MACD Histogram is above zero indicates a tug of war between buyers and sellers and a range bound market. The price is making lower low and RSI 14 is not making lower lows on Hourly charts indicating a trend reversal. However, The RSI 14 is around 40 levels and has not crossed midline level of 50. Thus the overall trend of Sensex looks to be in a range, and the markets might move either side. Buy on dips and sell on rise would be the best strategy to deploy for today’s market considering the overall trend of Sensex. We may expect a change in trend only if the price sustains below the support level or above the resistance level. I have provided Sensex Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Sensex Resistance 1 - 72825 Resistance 2 - 72930 Support 1 - 71935 Support 2 - 71830 Happy Learning, Happy Trading and have a wonderful day. Top Gainers: ITC, TMPV, ETERNAL Top Loser: HCL, HDFCBANK, SUNPHARMA

Sun Pharma slips back towards its June support

Sun Pharmaceutical Industries Limited,

Sun Pharma Advanced Research :Wins ₹27.51 Crore Tax Refund

DHARMESH BHATT (Research Analyst) SEBI Registration No. INH000009685

Sun Pharma Advanced wins ₹27.51 crore refund case

Sun Pharma Advanced Research Company Limited wins ₹27.51 crore CENVAT refund case. The CESTAT Mumbai has upheld the earlier order in favour of SPARC, with interest applicable where due. The tribunal dismissed the Revenue’s appeal and confirmed Sun Pharma Advanced Research Company Limited’s entitlement to a refund of accumulated CENVAT credit worth ₹27.51 crore. The matter had been disclosed by the company in August 2023 and is now decided in its favour. The amount is meaningful when compared with the company’s current financial scale. SPARC reported Q1 revenue of ₹40 crore and a net loss of ₹20.78 crore. The potential refund is therefore equivalent to nearly 69% of Q1 revenue and is larger than the quarterly loss. However, this should not be treated as recurring earnings, since the benefit relates to a past tax credit and the timing of the actual refund and interest, where applicable, will matter. My view is that the order improves SPARC’s near-term financial flexibility, but the bigger question remains its operating performance. Q1 revenue increased sharply from ₹9.6 crore to ₹40 crore, while the EBITDA loss narrowed to ₹27 crore from ₹48.2 crore. I would watch whether this revenue improvement continues and whether the EBITDA loss keeps narrowing over the next few quarters. The ₹27.51 crore refund can support liquidity, but it does not by itself change the underlying earnings profile. SPARC closed at ₹194.13 on the NSE on October 1. My stance remains cautious until operating losses show a sustained improvement. The key trigger to watch is the next quarterly result, particularly revenue growth and the pace of EBITDA loss reduction.

Sun Pharma Licenses Lerodalcibep Globally

Sun Pharma has entered into an exclusive global licensing agreement with US-based LIB Therapeutics to manufacture and commercialize Lerodalcibep across markets outside the United States and Greater China. Lerodalcibep is a once-monthly PCSK9 inhibitor designed to lower low-density lipoprotein cholesterol (LDL-C) in adults diagnosed with hypercholesterolemia and mixed dyslipidemia. Under the terms of the deal, LIB Therapeutics will receive an upfront payment alongside future milestone achievements and net-sales-linked royalties. The drug recently secured European Commission marketing authorization under the brand name Lyrokaul, following its US Food and Drug Administration (FDA) approval under the brand name Lerochol. This strategic partnership grants Sun Pharma entry into an ex-US/China PCSK9 market valued at ₹0.36 lakh crore ($3.7 billion) and growing at a 38% CAGR, with Europe accounting for ₹27,541 crore ($2.9 billion) as of MAT Q2 2026. Sun Pharma Managing Director Kirti W. Ganorkar noted that Lerodalcibep's low-volume injection, robust LDL-C efficacy, once-monthly dosing, and room-temperature stability for up to six months significantly enhance patient compliance. Sun Pharma will manage local regulatory filings across licensed territories, solidifying its specialty innovative portfolio and expanding its global footprint in cardiovascular therapy.

MACRO DATA--> UPDATE THAT BENEFIT THIS SECTORS STOCKS!

India’s foreign exchange reserves have witnessed another sharp decline. For the week ended September 25, 2026, India’s forex reserves fell by $18.34 billion to around $747.56 billion. This was the third consecutive weekly decline, with reserves falling by more than $38 billion over three weeks from the record high of around $785.71 billion reached earlier in September. But the bigger question for investors is: What does falling forex reserves mean for the Rupee and Indian stocks? Why Did Forex Reserves Fall? The biggest decline came from Foreign Currency Assets (FCAs). Foreign Currency Assets ↓ $15.57 billion to around $615.41 billion Gold reserves also declined by around $2.59 billion to approximately $108.70 billion. The fall comes amid pressure on the Indian Rupee, with the RBI intervening in the foreign exchange market to manage excessive currency volatility. ---->🇮🇳 What Does This Mean for the Rupee? The important transmission mechanism is: Forex Pressure → Rupee Pressure → USD/INR Moves Higher If the Rupee weakens against the US Dollar, companies that earn a significant portion of their revenue in dollars can benefit when those revenues are converted back into Rupees. This creates an important distinction: Weak Rupee = Negative for Importers --->IT AND PHARMA Sector Could Benefit